PKHD1 Carrier vs. ARPKD: What Your 23andMe Report Really Means

PKHD1 Carrier vs. ARPKD: What Your 23andMe Report Really Means

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: Autosomal recessive polycystic kidney disease (ARPKD) is caused by damaging variants on both copies of the PKHD1 gene. So a 23andMe report that flags one PKHD1 variant usually means you are a healthy carrier, not a patient. Government data put birth prevalence near 1 in 20,000, and population carrier frequency near 1 in 70. This article aggregates GeneReviews, NIH resources, expert consensus, and regulatory records to explain what that label does and does not mean.

What you’ll learn:

• Why one PKHD1 variant makes you a carrier, and why two are needed to cause ARPKD.
• The plain, absolute-number chance that a couple could have an affected child.
• How a consumer report differs from clinical-grade testing, and what a nephrologist or certified genetic counselor would actually do.
• Where treatment research stands, and how US and Canadian laws protect your genetic privacy.

How ARPKD Is Inherited and What a Carrier Result Means

ARPKD stands for autosomal recessive polycystic kidney disease. “Autosomal recessive” means a child must inherit a damaging gene change from both parents to be affected. The gene involved is PKHD1, and disease requires biallelic (two-copy) pathogenic variants in it.

PKHD1 gives the body instructions to make a protein called fibrocystin, also known as polyductin. This protein sits mostly in kidney cells and, to a smaller degree, liver cells. It helps cells grow, stick together, and build the tiny tubes that filter your blood. Much of this work happens at the primary cilium, a tiny antenna-like structure on the cell surface that senses fluid flow. When fibrocystin does not work properly, kidney tubes can widen into cysts instead of forming clean channels. The same protein complex is active in the liver’s bile ducts, which is why the disease, when it occurs, affects both organs rather than the kidneys alone.

Think of it like a pair of matching keys. You inherit one copy of PKHD1 from each parent. If just one key is bent (one variant), the other working key still runs the lock. You are an unaffected carrier, not a patient. Only when both keys are bent does the lock fail and ARPKD can develop. This two-copy rule is the single most important idea for reading a carrier report calmly.

It also explains why ARPKD is different from the more familiar adult form. Here is how the two forms compare:

Feature	ARPKD (recessive)	ADPKD (dominant)
Copies needed to cause disease	Two altered copies (biallelic)	One altered copy
Typical age at onset	Infancy / around birth	Adulthood
Organs involved	Kidneys and liver	Mainly kidneys
Inheritance pattern	Autosomal recessive	Autosomal dominant

The words “polycystic kidney disease” cover both, but the inheritance rules and timing are not the same.

Here is the catch with consumer reports. PKHD1 is one of the largest genes in the human genome, with hundreds of reported variants. A 23andMe carrier report typically checks only a limited set of those variants. So a “single variant detected” result does not confirm your full status, and even a “no variant” result cannot fully rule carrier status out. That is a real limit, not a technicality. Because a single tested variant is being read against such a large gene, clinical confirmation is what turns a raw label into reliable information.

If a report has left you anxious, the most useful first step is a conversation with your primary care physician or a certified genetic counselor. You can find one through the National Society of Genetic Counselors at NSGC.org. They can explain what your specific report tested and what it did not. That single conversation often replaces days of online worry with a clear plan.

Section recap: ARPKD needs two damaging PKHD1 copies, so a single flagged variant means carrier status, not disease. Consumer panels test only some variants, so confirm the result clinically.

Absolute Risk: What the Numbers Really Mean for a Couple

Relative-risk language can sound scary. Translating it into plain numbers helps. When both partners are confirmed carriers of a pathogenic PKHD1 variant, each pregnancy carries a fixed set of odds:

• 1 in 4 (25%): a child affected with ARPKD.
• 2 in 4 (50%): an unaffected carrier, just like the parents.
• 1 in 4 (25%): a child who inherits neither variant.

These odds reset with every pregnancy, like flipping a fresh coin each time. A couple who has already had one unaffected child still faces the same 25% figure with the next pregnancy, because past outcomes do not change future odds.

But this only applies if both partners carry a pathogenic variant. If only one parent is a confirmed carrier and the other is not, the couple cannot have an affected child through PKHD1 alone, because two damaged copies are required. Their children would face only the possibility of being carriers themselves, not of having the disease. This is exactly why partner testing sits at the center of any risk assessment.

Now the population context, which is where the anxiety usually eases. General-population carrier frequency is roughly 1 in 70 to 1 in 80 people. In plain terms, being a PKHD1 carrier is fairly common and is not a rare misfortune. Birth prevalence of ARPKD, by contrast, is only about 1 in 20,000 to 1 in 25,000 live births. That large gap between how many people carry a variant and how few children are affected exists precisely because both parents must carry and both must pass on a variant. So even carrying one variant does not, by itself, mean a high chance of an affected child.

A certified genetic counselor can turn your specific test results into personalized numbers. General figures are a starting point, not a verdict. For example, a counselor can factor in ancestry, family history, and whether your partner has been tested, all of which shift the real-world estimate. A counselor listed at NSGC.org can walk through your family’s situation.

Section recap: Two confirmed carriers face a 25% chance of an affected child per pregnancy, but carrier frequency (about 1 in 70) is far higher than disease prevalence (about 1 in 20,000). Partner status drives the real risk.

Testing Options: Consumer Screens vs. Clinical Diagnostics

Not all genetic tests are equal. A useful comparison is a home blood-pressure cuff versus a full cardiology workup. Both look at the heart, but only one guides medical decisions. Here is how the two testing routes differ:

Feature	Direct-to-consumer (23andMe, AncestryDNA)	Clinical-grade testing
Variants checked	A limited, fixed set	Expanded panels or full PKHD1 sequencing
Purpose	Informational only	Guides medical decisions
Laboratory standard	Consumer lab	Accredited (CLIA/CAP) lab
Can it confirm status?	No; confirm clinically	Yes, when interpreted by a clinician

Direct-to-consumer (DTC) reports, such as 23andMe and AncestryDNA, are marketed as informational. They test a limited set of variants and are not designed to be the final word for medical action. A negative or single-variant DTC result does not fully rule carrier status in or out and should be confirmed clinically before medical decisions. Clinical guidance treats these reports as a prompt to investigate, not as a diagnosis in themselves.

Clinical-grade options are broader and more thorough. Expanded carrier screening panels can screen 100 or more genes at once, and full PKHD1 gene sequencing is offered through laboratories such as Invitae. Full sequencing reads the whole gene rather than a fixed shortlist of spots, which matters a great deal for a very large gene. Professional guidance recommends that carrier screening be performed in a clinically accredited (CLIA/CAP) laboratory using validated methods. The American College of Medical Genetics and Genomics (ACMG) recommends offering expanded carrier screening to all pregnant patients and those planning pregnancy.

For couples thinking about future children, reproductive-testing pathways exist. These include partner carrier testing and, where relevant, prenatal or preimplantation genetic testing (testing embryos before pregnancy). The right pathway depends on both partners’ results and on personal values, so there is no single “correct” choice. During pregnancy, fetal ultrasound may show findings such as enlarged, bright (echogenic) kidneys, which can prompt further evaluation.

These pathways involve real trade-offs and personal values. A nephrologist and a certified genetic counselor can explain your options in detail, including cost, timing, and what each test can and cannot tell you. You can locate a counselor at NSGC.org before making any testing decision.

Section recap: Consumer reports are a screening starting point, not a diagnosis. Clinical-grade sequencing in an accredited lab, guided by a counselor, is the standard for medical decisions.

Clinical Interpretation: Carrier, Affected, or Uncertain

A genetic result usually falls into one of three practical buckets for a reader. Understanding which one you are looking at changes everything:

• Unaffected carrier: one pathogenic PKHD1 variant, no disease. A healthy adult carrier generally has no ARPKD symptoms and does not develop the condition.
• Affected individual: two pathogenic variants, which is what causes ARPKD.
• Variant of uncertain significance (VUS): a change whose disease impact has not yet been established.

The VUS category deserves special care. ACMG/AMP variant-classification standards define five tiers: pathogenic, likely pathogenic, VUS, likely benign, and benign. These standards weigh several kinds of evidence together. That evidence includes how common a variant is in the population, computer predictions, laboratory studies of the protein, and how the variant tracks with disease in families. A VUS lands in the middle because the evidence does not yet point clearly in either direction. It should not be used to drive medical decisions until more evidence reclassifies it. Because PKHD1 is so large, with hundreds of variants, VUS findings are common. Reclassification can happen over time as labs gather more data, and a VUS today may later become “likely benign” or “likely pathogenic”.

It is like a weather forecast marked “uncertain.” You would not cancel a wedding based on it, but you would keep watching. A VUS calls for professional interpretation, not panic or action. Many people who receive a VUS never need to change anything about their care.

Only a clinician, ideally paired with a certified genetic counselor, can combine a genetic result with family history, symptoms, and imaging to reach an actual diagnosis. A raw report cannot do that on its own. The classification standard itself was written for clinical laboratories, which is part of why consumer reports and clinical testing are not interchangeable. A clinical lab documents the exact variant, its classification, and the evidence behind it, so a clinician can act on solid ground rather than a single label.

If your result mentions a VUS, or if you are simply unsure which of the three buckets applies to you, that uncertainty is exactly what a professional appointment is for. Book time with a genetic counselor through NSGC.org, and bring your report with you so the discussion starts from your actual data.

Section recap: Results split into carrier, affected, or uncertain (VUS). A VUS should not drive medical action until reclassified, and only a clinician can turn any result into a diagnosis.

The Clinical Picture, Surveillance, and Early Detection

When ARPKD is actually present, it usually shows up early. The condition typically presents in the perinatal or neonatal period, meaning around birth or in the first weeks of life. Classic findings include enlarged, echogenic (bright on ultrasound) kidneys and reduced kidney function.

ARPKD is not only a kidney condition. It is the prototype of the hepato-renal fibrocystic diseases, meaning it affects the liver as well. The liver problem, called congenital hepatic fibrosis, comes from a developmental change in the bile-duct system known as ductal plate malformation. Essentially all patients have some degree of this liver scarring from birth. Over time it can cause portal hypertension, which is high pressure in the vein that carries blood to the liver. Older patients may also develop an enlarged spleen (splenomegaly) and bile-duct infections (cholangitis).

The outlook varies widely from child to child. NIH data note that about 30% of newborns with ARPKD die within the first week of life, largely from breathing problems tied to underdeveloped lungs. That figure is sobering, but it also means most who survive the first week face a very different path. Those who get through the newborn period have a good chance of surviving into adulthood. Severity is driven partly by the specific PKHD1 changes, with two truncating (protein-shortening) variants tending toward more severe disease. This range, from severe perinatal presentation to milder later-childhood presentation, is one reason expert care is individualized.

For affected children, an international expert consensus lays out a multidisciplinary surveillance framework. That framework grew out of an international conference that produced agreed diagnostic criteria and a shared plan for follow-up. It includes ongoing monitoring of several areas:

• Blood pressure
• Kidney function
• Growth
• Liver and portal-hypertension complications
• Perinatal interventions and behavioral assessment for affected children

Management is supportive and coordinated across specialists such as nephrology, hepatology, and nutrition. Early referral to pediatric nephrology is the concrete, evidence-based action available today.

One reassuring point: healthy carriers do not develop ARPKD and do not need ARPKD surveillance. Surveillance is for affected children, not for carriers. In other words, a carrier report on its own is not a reason to start kidney scans or specialist visits for yourself. What it can do is inform reproductive planning, which is a different conversation from personal disease monitoring.

If a child in your family does have kidney or liver findings, early and coordinated care is what the evidence supports. A nephrologist can track kidney function and blood pressure over time, and a hepatology team can watch for liver and portal-hypertension complications. A genetic counselor at NSGC.org can connect the genetic result to that clinical picture. The practical message is hopeful: many affected children who survive infancy go on to live into adulthood with structured, multidisciplinary care.

Section recap: ARPKD, when present, usually appears near birth with enlarged kidneys and liver fibrosis, and affected children need multidisciplinary monitoring. Carriers do not need surveillance.

Latest Treatment Landscape and Regulatory Status

Today, the backbone of ARPKD care is supportive management, not a cure. This means controlling blood pressure, supporting nutrition and kidney function, and monitoring liver complications such as portal hypertension and cholangitis. Supportive care is not “doing nothing.” It is a coordinated effort to protect kidney and liver function for as long as possible. Think of careful maintenance that keeps an aging engine running smoothly, even when no single repair fixes everything at once. An international consensus confirms that management is supportive and multidisciplinary. At the time of that consensus, no ARPKD-specific disease-modifying drug had been approved.

Here is where a common mix-up must be cleared up carefully. Tolvaptan, sold as Jynarque in the US and Jinarc in Canada and Europe, is a drug that slows kidney-function decline. It was the first FDA-approved therapy for the autosomal dominant form of the disease, ADPKD, in adults at risk of rapid progression. That is a different condition from ARPKD.

The regulatory record is specific:

• FDA (US): Jynarque approved for adult ADPKD on 2018-04-23.
• Health Canada: Jinarc authorized for ADPKD on 2015-02-23.
• Safety controls: because of serious liver-injury risk, Jynarque carries a boxed warning and is available only through a REMS restricted-distribution program with scheduled ALT/AST/bilirubin blood monitoring.
• ARPKD status: not approved by either the FDA or Health Canada; its use in ARPKD is investigational.

Two ongoing multinational, open-label Phase 3 trials are testing tolvaptan in children with ARPKD: Study 204 and Study 307. The two studies differ in who they enroll and how long treatment runs:

Feature	Study 204	Study 307
Age enrolled	28 days to under 12 weeks, with signs of rapid progression	28 days to under 18 years
Treatment period	24 months, optionally up to 36	18 months
Design	Open-label Phase 3	Open-label Phase 3

Study 204’s rapid-progression signs can include very enlarged kidneys, multiple or microcysts, and low amniotic fluid before birth. Outcomes across both trials include safety, change in kidney function, and the proportion needing kidney replacement therapy compared with historical data, with primary completion reported for 2025-12. Because both trials are open-label, meaning participants and doctors know the treatment is being given, the published results will need careful reading once they arrive.

These trials are meaningful because they test the question directly rather than assuming that a drug helpful in the dominant form must also help in the recessive form. Until results are published and reviewed, though, tolvaptan for ARPKD stays in the research column.

So the honest summary is this: tolvaptan is an approved ADPKD drug and a research-stage possibility for ARPKD, nothing more today. Any treatment decision belongs with a nephrologist, and a genetic counselor at NSGC.org can help you understand the difference. If you read a headline that blends the two forms together, this distinction is the thing to double-check.

Section recap: ARPKD care is supportive today. Tolvaptan is FDA/Health Canada approved for ADPKD (2018/2015) with a boxed warning, but remains investigational for ARPKD in Phase 3 pediatric trials.

Family Implications and Cascade Testing

A confirmed carrier result is never just about one person. It ripples outward to siblings, parents, and future children. Genetic professionals use a structured approach called cascade testing to make sense of this.

Cascade testing is the systematic, targeted testing of at-risk relatives once a pathogenic variant is identified in a family. Once your specific variant is known, relatives can be tested for that exact change, which is simpler and more precise than screening from scratch. Its advantages include several practical points:

• It lets each relative learn their own carrier status.
• Targeting one known variant is faster than a broad panel, since the lab knows exactly what to look for.
• It tends to cost less than screening a relative from scratch.

Because ARPKD is recessive, a carrier’s siblings each have a meaningful chance of also being carriers. This matters most when those relatives are planning pregnancies, since two carriers in a couple are what create reproductive risk. A sibling who learns they are a carrier can then have their own partner tested. The same 25% math from earlier applies only if both members of that couple carry a variant. Think of it like a shared family map: once one landmark is confirmed, the rest of the map becomes far easier to read.

A certified genetic counselor is the guide here. They help families decide who to test, interpret results in the context of family history, and support the sometimes-difficult disclosure conversations. Deciding whom to tell, and how, is rarely simple. Some relatives will want to know their status right away, while others may prefer not to test at all, and both choices are valid. A counselor can help you frame the conversation so that relatives receive the information without pressure. NSGC framing also stresses something important for peace of mind: carrier status is common and is not a personal fault.

If you are wondering how to raise this with siblings or parents, you do not have to figure it out alone. A counselor found through NSGC.org can help you plan both the testing and the conversation.

Section recap: Cascade testing lets relatives check for your exact variant, which matters most for siblings planning pregnancies. A genetic counselor guides who to test and how to talk about it.

Psychosocial Impact, Privacy, and Insurance Protections

Seeing “kidney disease” next to your name is unsettling, even when you are a healthy carrier. That anxiety is normal, and it often comes with practical worries about privacy and insurance. Both deserve clear answers. The two countries covered here protect genetic information differently:

Protection	United States (GINA, 2008)	Canada (2017 Act)
Health insurance	Protected	Protected
Employment	Protected	Protected across contracts/services
Life insurance	Not covered	Covered by wording, but limited in practice
Disability / long-term-care insurance	Not covered	Broadly addressed by the Act

In the United States, the Genetic Information Nondiscrimination Act of 2008 (GINA) is the key protection. GINA prohibits health insurers and employers from using genetic information to discriminate, such as denying coverage or setting premiums based on carrier or predisposition results. A carrier result, being unaffected, falls squarely within GINA’s health-insurance and employment protections.

But GINA has a widely noted gap. It does not cover life insurance, disability insurance, or long-term-care insurance. It also protects results obtained before symptoms or diagnosis, not the use of an already-manifested disease. So the law is strong for health coverage and jobs, but not a complete shield.

Canada takes a broader approach. The Genetic Non-Discrimination Act of 2017 prohibits requiring or using a genetic test or its results as a condition of providing goods, services, or entering a contract, including insurance. These protections are broader than US GINA, reaching across contracts and services rather than only health insurance and employment. The Supreme Court of Canada upheld the Act’s constitutionality in 2020. Even so, real-world studies note the Act’s practical impact on life-insurance underwriting has been limited despite the broad language.

A practical way to think about the two systems is this. Imagine two locked doors marked “privacy.” In the US, GINA firmly bolts the doors labeled “health insurance” and “employment,” but leaves the “life, disability, and long-term-care insurance” door open. In Canada, the 2017 law tries to bolt far more doors across contracts and services. In practice, though, one of them, life-insurance underwriting, has not shut as tightly as the wording suggests. Knowing which doors are closed helps you decide what, if anything, to disclose and when.

For the emotional side, you do not have to carry the worry alone. Certified genetic counselors provide both information and support, and reputable patient organizations such as the PKD Foundation offer community and resources. NSGC framing is worth repeating here: carrier status is common and is not a personal fault, so a report is information to act on, not a source of shame. A counselor at NSGC.org can help you weigh disclosure decisions. This article is educational and is not a substitute for that professional guidance.

Section recap: In the US, GINA blocks health-insurance and employment discrimination but not life, disability, or long-term-care insurance. Canada’s 2017 law is broader. Counselors and patient groups offer real support.

Frequently Asked Questions

Will I get the disease? Almost certainly not from a single PKHD1 variant. ARPKD is autosomal recessive, so one variant makes you an unaffected carrier, not a patient. A healthy adult carrier typically has no ARPKD symptoms and does not develop the condition. Still, confirm your result with clinical testing and discuss it with a clinician.

Will my children inherit it? Only if both you and your partner pass on a pathogenic PKHD1 variant. If both parents are confirmed carriers, each pregnancy carries a 25% chance of an affected child. If only one parent carries a variant, an affected child is not possible through PKHD1 alone. Partner testing is the key next step.

Will this affect my health or life insurance? In the US, GINA blocks health insurers and employers from discriminating based on genetic information, but it does not cover life, disability, or long-term-care insurance. Canada’s 2017 law offers broader protection across contracts and services. A genetic counselor can help you think through disclosure.

Can my employer find out? In the US, GINA prohibits employers from using genetic information, including a carrier result, to make employment decisions. This is one of the law’s core protections. For specifics about your situation, a certified genetic counselor at NSGC.org can help.

Should I get a second opinion? Yes, confirming a consumer result is standard, not excessive. A DTC report flagged as informational should be confirmed in an accredited clinical laboratory before it drives medical decisions. Then consult a nephrologist and a certified genetic counselor to interpret the full picture. It also helps to know the difference between the two forms of the disease. ADPKD is dominant and usually adult-onset, while ARPKD is recessive and typically appears in infancy with both kidney and liver involvement. A second opinion is especially wise if a report or article seems to blur those two conditions together.

Summary

A 23andMe report that flags one PKHD1 variant usually points to a healthy carrier, not a diagnosis of ARPKD. The disease requires two damaging copies of the gene, and a single variant on a limited consumer panel neither confirms nor fully rules out your status. Population carrier frequency (about 1 in 70) is far higher than disease prevalence (about 1 in 20,000). The real reproductive risk therefore depends on whether a partner also carries a variant.

Confirming the result in an accredited clinical laboratory, considering partner testing, and consulting a nephrologist and a certified genetic counselor are the concrete next steps. On treatment, care is supportive today; tolvaptan is approved only for the dominant form (ADPKD) and remains investigational for ARPKD in Phase 3 pediatric trials. And your genetic information carries legal protections. Those protections are strong for US health coverage and jobs under GINA, and broader in Canada, though not without gaps.

If you take one thing from this article, let it be the two-copy rule. A carrier report describes a single altered copy, and a single copy does not cause ARPKD. The most useful next steps are calm and concrete: confirm the finding with clinical testing, discuss partner testing, and book time with a nephrologist and a certified genetic counselor. The goal of this piece is to give you the vocabulary for a productive appointment, not to replace one. A counselor listed at NSGC.org is the right person to turn general information into a plan that fits your family. Facing a genetic report with the correct facts, rather than worst-case guesses, is often the fastest way to move from anxiety back to a sense of control.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. Sweeney WE, Avner ED. Polycystic Kidney Disease, Autosomal Recessive (ARPKD – PKHD1). GeneReviews, University of Washington / NCBI Bookshelf (last updated 2019). https://www.ncbi.nlm.nih.gov/books/NBK1326/
2. Guay-Woodford LM, Bissler JJ, Braun MC, et al. Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international conference. J Pediatr. 2014;165(3):611-617. https://pubmed.ncbi.nlm.nih.gov/25015577/
3. NIDDK, National Institutes of Health. Autosomal Recessive Polycystic Kidney Disease (ARPKD). https://www.niddk.nih.gov/health-information/kidney-disease/polycystic-kidney-disease/autosomal-recessive-pkd
4. MedlinePlus Genetics, National Library of Medicine (NIH). PKHD1 gene. https://medlineplus.gov/genetics/gene/pkhd1/
5. Erger F, Aliu N, Anslinger K, et al. Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease. BMC Nephrol. 2023;24:24. https://pmc.ncbi.nlm.nih.gov/articles/PMC9926647/
6. FDA (Jynarque prescribing information) / Health Canada (Jinarc product monograph). Tolvaptan regulatory status for polycystic kidney disease. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204441s000lbl.pdf
7. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the ACMG and the AMP. Genet Med. 2015;17(5):405-424. https://pubmed.ncbi.nlm.nih.gov/25741868/
8. Gregg AR, et al. (ACMG). Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: an ACMG practice resource. Genet Med. 2021. https://pubmed.ncbi.nlm.nih.gov/34285390/
9. US EEOC / NHGRI (NIH). Genetic Information Nondiscrimination Act of 2008 (GINA). https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
10. Government of Canada. Genetic Non-Discrimination Act (S.C. 2017, c. 3). https://laws-lois.justice.gc.ca/eng/acts/G-2.5/
11. National Society of Genetic Counselors (NSGC). Cascade genetic testing and family communication of genetic risk information. https://www.nsgc.org/Policy-Research-and-Publications/Position-Statements
12. Guay-Woodford LM. Autosomal recessive polycystic kidney disease: the prototype of the hepato-renal fibrocystic diseases. Review, 2014. https://pubmed.ncbi.nlm.nih.gov/25113295/

Last updated: 2026-08-14

Author: Genelumen editorial team. This article aggregates 12 sources from peer-reviewed medical literature and public health agencies (tier 1=8 / tier 2=4), including NIH/NIDDK, MedlinePlus, Health Canada, FDA, ACMG/AMP guidelines, NSGC, and PubMed-indexed publications.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

Related: Genetic Diseases category

🇯🇵 For readers in Japan — a separate Japanese edition written for Japan’s healthcare system (not a translation): https://genelumen.com/ja/ja-genetic-diseases/arpkd-pkhd1-inheritance-carrier-guide